Chamindi Seneviratne
Overview
Explore the profile of Chamindi Seneviratne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shetty A, Sivinski J, Cornell J, McCracken C, Sadzewicz L, Mahurkar A, et al.
Sci Rep
. 2024 May;
14(1):10733.
PMID: 38730024
Molecular responses to alcohol consumption are dynamic, context-dependent, and arise from a complex interplay of biological and external factors. While many have studied genetic risk associated with drinking patterns, comprehensive...
2.
Tiouririne N, Kalelioglu T, Seneviratne C, Wang X
Alcohol Alcohol
. 2023 Dec;
59(2).
PMID: 38069498
Topiramate (TPM), a GABA/glutamate modulator, has shown positive results for treating alcohol use disorder (AUD), but causes significant cognitive adverse effects. TPM causes cognitive side effects by reducing glutathione levels...
3.
Mullins K, Seneviratne C, Shetty A, Jiang F, Christenson R, Stass S
Clin Biochem
. 2023 May;
118:110583.
PMID: 37182637
Introduction: Nucleic acid sequencing technologies have advanced significantly in recent years, thereby allowing for the development of liquid biopsies as new means to detect cancer biomarkers and cancer heterogenicity. Most...
4.
Hare S, Adhikari B, Mo C, Chen S, Wijtenburg S, Seneviratne C, et al.
Neuropsychopharmacology
. 2023 Apr;
48(11):1594-1601.
PMID: 37118058
Cognitive impairments predict poor functional outcomes in people with schizophrenia. These impairments may be causally related to increased levels of kynurenic acid (KYNA), a major metabolic product of tryptophan (TRYP)....
5.
Shetty A, Sivinski J, Cornell J, Sadzewicz L, Mahurkar A, Wang X, et al.
medRxiv
. 2023 Mar;
PMID: 36993621
Molecular changes associated with alcohol consumption arise from complex interactions between pharmacological effects of alcohol, psychological/placebo context surrounding drinking, and other environmental and biological factors. The goal of this study...
6.
Seneviratne C, Shetty A, Geng X, McCracken C, Cornell J, Mullins K, et al.
Diagnostics (Basel)
. 2022 Dec;
12(12).
PMID: 36552904
Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC), which constitutes the majority of lung cancers, is significantly more responsive...
7.
Seneviratne C, Noel J, Franklin P, Colloca L
Front Psychiatry
. 2022 Sep;
13:1022762.
PMID: 36172509
No abstract available.
8.
Cornell J, Taj A, Sivinski J, Yin M, Bhatia P, Oula D, et al.
Front Commun (Lausanne)
. 2022 Sep;
7.
PMID: 36081878
Background: The Society of Interdisciplinary Placebo Studies (SIPS) was one of many organizations that hosted a virtual scientific conference in response to the COVID-19 pandemic restrictions. Retaining essential benefits of...
9.
Seneviratne C, Gorelick D, Lynch K, Brown C, Romer D, Pond T, et al.
Alcohol Clin Exp Res
. 2022 Sep;
46(10):1900-1912.
PMID: 36055978
Background: In a previous study, ondansetron, a serotonin 5-HT receptor antagonist, reduced drinking intensity (drinks/drinking day [DPDD]) among European-ancestry (EA) participants with moderate-to-severe alcohol use disorder (AUD) and variants in...
10.
Cornell J, Conchas A, Wang X, Fink J, Chen H, Kane M, et al.
Alcohol Clin Exp Res
. 2022 Aug;
46(10):1888-1899.
PMID: 36031718
Background: The serotonin transporter (SERT) mRNA was previously reported to be a quantitative and pathophysiology-based biomarker of heavy drinking in 5HTTLPR:LL genotype-carriers treated with ondansetron. Here, we validated the potential...